Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an announcement.
BioArctic AB’s partner Eisai announced that Leqembi® (lecanemab) has been approved for once every four weeks intravenous maintenance treatment for early Alzheimer’s disease by China’s National Medical Products Administration. This approval marks a significant advancement in Alzheimer’s treatment, as Leqembi is the only approved therapy targeting both amyloid plaque and protofibrils, potentially impacting the disease’s progression. The approval strengthens BioArctic’s market position and offers new opportunities for commercialization in China, benefiting stakeholders involved in Alzheimer’s disease treatment.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. The company is known for inventing Leqembi® (lecanemab), the first drug proven to slow the progression of Alzheimer’s disease and reduce cognitive impairment in its early stages. BioArctic collaborates with Eisai for the global regulatory and commercialization efforts of Leqembi, and also has a research portfolio targeting Parkinson’s disease, ALS, and other Alzheimer’s treatments.
YTD Price Performance: 43.16%
Average Trading Volume: 307,295
Technical Sentiment Signal: Buy
Current Market Cap: SEK25.28B
For detailed information about BIOA.B stock, go to TipRanks’ Stock Analysis page.